CU20130012A7 - CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE - Google Patents

CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE

Info

Publication number
CU20130012A7
CU20130012A7 CUP2013000012A CU20130012A CU20130012A7 CU 20130012 A7 CU20130012 A7 CU 20130012A7 CU P2013000012 A CUP2013000012 A CU P2013000012A CU 20130012 A CU20130012 A CU 20130012A CU 20130012 A7 CU20130012 A7 CU 20130012A7
Authority
CU
Cuba
Prior art keywords
csf
conjugate
stimulating factor
granulocit
colonia
Prior art date
Application number
CUP2013000012A
Other languages
Spanish (es)
Other versions
CU24139B1 (en
Inventor
Tatyana Veniaminovna Chernovskaya
Dmitriy Valentinovich Morozov
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Angelina Vsevolodovna Klenova
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CU20130012(A7) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of CU20130012A7 publication Critical patent/CU20130012A7/en
Publication of CU24139B1 publication Critical patent/CU24139B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se relaciona con productos farmacéuticos y el sector de la medicina, específicamente,con un nuevo conjugado fisiológicamente activo de factor estimulante de colonia de granulocito ( G-CSF) con la fórmula general: donde: n-es un número entero de 681 a 1 000; m-entero>4; NaH-G-CSF-es un polipéptido natural o recombinante, teniendo actividad de G-CSF. La invención también está relacionada con medicamentos conteniendo el conjugado de fórmula (1), composiciones farmacéuticas con el factor estimulante de colonia de granulocito como un ingrediente activo, y un contenedor que contiene la composición farmacéutica, útiles para prevenir y/o tratar la neutropenia.The present invention relates to pharmaceuticals and the medical sector, specifically, to a new physiologically active conjugate of granulocyte colony stimulating factor (G-CSF) with the general formula: where: n-is an integer of 681 to 1,000; m-integer> 4; NaH-G-CSF-is a natural or recombinant polypeptide, having G-CSF activity. The invention is also related to medicaments containing the conjugate of formula (1), pharmaceutical compositions with granulocyte colony stimulating factor as an active ingredient, and a container containing the pharmaceutical composition, useful for preventing and / or treating neutropenia.

CU20130012A 2010-08-13 2011-07-19 CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE CU24139B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent
PCT/RU2011/000532 WO2012021088A1 (en) 2010-08-13 2011-07-19 A novel conjugate of granulocyte colony-stimulating factor (g-csf) with polyethylene glycol

Publications (2)

Publication Number Publication Date
CU20130012A7 true CU20130012A7 (en) 2013-04-19
CU24139B1 CU24139B1 (en) 2015-12-23

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20130012A CU24139B1 (en) 2010-08-13 2011-07-19 CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE

Country Status (17)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
ES2691493T3 (en) 2012-06-07 2018-11-27 Childrens Hospital Los Angeles Methods to treat neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
JP6742300B2 (en) * 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド Novel process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
BR112022018501A2 (en) * 2020-03-17 2022-10-25 Drugrecure Aps LIQUID FORMULATION OF GM-CSF FOR INHALATION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease

Also Published As

Publication number Publication date
CU24139B1 (en) 2015-12-23
EA201101035A1 (en) 2012-02-28
RU2446173C1 (en) 2012-03-27
CO6670557A2 (en) 2013-05-15
PE20131085A1 (en) 2013-10-10
DOP2013000003A (en) 2013-07-31
CN103140499A (en) 2013-06-05
MA34525B1 (en) 2013-09-02
KR101549457B1 (en) 2015-09-02
SG187572A1 (en) 2013-03-28
MY160732A (en) 2017-03-15
WO2012021088A1 (en) 2012-02-16
ECSP13012399A (en) 2013-05-31
NI201300007A (en) 2014-05-26
KR20130043167A (en) 2013-04-29
EA019043B1 (en) 2013-12-30
CN103140499B (en) 2014-12-17
CL2013000400A1 (en) 2013-07-26
RS20130094A1 (en) 2013-08-30
CR20130020A (en) 2013-02-20

Similar Documents

Publication Publication Date Title
CU20130012A7 (en) CONJUGATE OF COLONIA STIMULATING FACTOR OF GRANULOCIT (G-CSF) WITH GLYCOL POLYETHYLENE
BR112013003045A2 (en) compound and pharmaceutical composition and uses thereof, sterile container and method for preparing pharmaceutical composition for administration
EA201690102A1 (en) PHARMACEUTICAL COMPOSITION CONTAINING DIMETHYLFUMATE FOR INTRODUCTION TO LOW DAILY DOSE
CY1119616T1 (en) HUMAN ANTI-DUMP DRUG CONSUMPTION AGAINST TISSUE
MX2014009757A (en) Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy.
UA109010C2 (en) Morpholino pyrividines and their use in therapy
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
EA201490521A1 (en) OPTIONS OF FIBROBLAST GROWTH FACTOR 21
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
TN2015000187A1 (en) Triazolopyrazine
WO2013101897A3 (en) Improved compositions and methods for delivery of omeprazole plus acetylsalicylic acid
BR112015012366A8 (en) cxcr7 antagonists, their use, pharmaceutical composition, as well as methods for detecting high levels of cxcr7 in a sample and for imaging a tumor, organ, or tissue
CU23734A1 (en) IMMUNOMODULATOR POLIPEPTIDES DERIVED FROM IL-2 WITH ANTIGONIST ACTIVITY OF THIS CITOCINE USED IN CANCER THERAPY AND CHRONIC INFECTIOUS DISEASES
BR112013031268A2 (en) "pramlintide analog polypeptides, use thereof, pharmaceutical composition comprising said polypeptides and method of preparing said composition".
EA201590835A1 (en) COMPOSITIONS WITH LOW DOSE OF PANCRELIPASE AND INTESTINAL COATING
WO2010083434A3 (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
AR068816A1 (en) COMPOSITIONS OF BRIMONIDINE IMPROVED FOR THE TREATMENT OF ERYTHEMA
EA201291089A1 (en) METHOD FOR OBTAINING PHARMACEUTICAL PREPARATIONS INTENDED FOR ORAL ADMINISTRATION, CONTAINING ONE OR MORE ACTIVE INGREDIENTS AND CONTAINING COMPOSITIONS
BR112015025804A2 (en) glutarimide derivatives, their use, pharmaceutical composition based on them and methods for the production of glutarimide derivatives
MX2015004362A (en) Ketamine derivatives.
CR20140540A (en) NEW DOSAGE FORM AND FORMULATION OF ABEDITEROL
MX2014014041A (en) Novel dosage and formulation.
CY1117596T1 (en) PHARMACEUTICAL AIRPORT COMPOSITIONS OF FORMOTEROL AND DIPROPIONAL VEHICLE
EA201300857A1 (en) PYRAZOLES AS AN ANTAGONISTS CRTH2
BR112013032911A2 (en) leukotoxin e / d as a new anti-inflammatory and microbicidal agent